In a phase I/II study conducted by Seledtsov and coworkers, 40 patients with stage III/IV malignant melanoma were treated with a poly-epitopic xenogeneic DNA cancer vaccine prepared from murine B16 and LLC murine melanoma cell lysates, combined with subcutaneous recombinant IL-2 injection. Here, IL2 is linked to melanoma.